Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Inclusion Criteria: * Any age at diagnosis. * Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular, unfavorable subtype) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites. * Patients must have high-risk neuroblastoma defined as one of the following: * Any age with International Neuroblastoma Risk Group (INRG) stage L2 or M and MYCN amplification. * Age ≥ 547 days and INRG stage M regardless of biologic features. * Age ≥ 547 days and INRG stage L2 with unfavorable histology. * Patients must have newly diagnosed disease. * Patients must have either measurable or evaluable disease by INRC. * Patients observed or treated with a single cycle of chemotherapy per a low- or intermediate-risk neuroblastoma regimen (e.g. as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease, but subsequently found to meet high-risk criteria will be eligible. These patients must enroll prior to the start of high-risk therapy. * Patients who receive localized emergency radiation to sites of life-threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis will be eligible. * Patients initially recognized to have high-risk disease must enroll prior to or within the first week after starting high-risk induction chemotherapy. * Induction therapy as per a standard high-risk neuroblastoma i…